2011.10.31 Weekly Broadcast Email
The following updates were made to the CCCWF CCOP Research Base website for the week of October 31, 2011.
91105(Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients)
Announcement from study PI:
91105 is nearing completion of enrollment with 193 of 200 participants enrolled. We still need additional enrollments to reach our goal, however. Please try to help us reach our goal by December. Also, please send in the MRIs as soon as possible so we can process your reimbursement. Thanks!!
Steve Rapp, PhD, PI
Annual Meeting Presentations:
The 2011 Annual Meeting presentations have been uploaded to the website and are located on the annual meeting page.
Adverse Events:
There were no adverse events received during the month of October. A summary of past adverse event reports is located on the Adverse Event webpage.
Accrual Totals:
During the month of October, 14 patients were accrued to CCCWF CCOP Research Base trials. Congratulations to North Shore University Hospital for accruing the most patients. See the Research Base website spotlight section for further information.
Lisa Autry-
Wake Forest Baptist Health
Department of Radiation Oncology
Research Base Protocol Information Office
2000 West First Street, Suite 401
Winston-Salem, NC 27104
Phone: 336-716-0891
Fax: 336-716-6275
**Please note my email address change lautry@wakehealth.edu
CONFIDENTIAL AND PRIVILEGED: The information contained in this electronic message may be privileged and confidential information intended for the sole use of the addressee and any personnel receiving a copy. If the reader of this electronic message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this electronic message in error, please notify me immediately by responding to this message.
WITHHOLD FROM PUBLIC DISCLOSURE UNDER N.C.G.S. 104E-9(a)(4)